Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Access Support Resource Center

Featured

Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
US Cancer Centers Still Struggling with Chemotherapy Shortages, NCCN’s Recent Survey Reveals
11/04/2023

Brandon Twyford

Brandon Twyford
Results from NCCN's recent survey of cancer centers reveals a persisting shortage of chemotherapy drugs within the US, with 72% of centers reporting a shortage of carboplatin and 59% facing challenges with obtaining cisplatin.
Results from NCCN's recent survey of cancer centers reveals a persisting shortage of chemotherapy drugs within the US, with 72% of centers reporting a shortage of carboplatin and 59% facing challenges with obtaining cisplatin.
Results from NCCN's recent...
11/04/2023
Journal of Clinical Pathways
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023

Grace Taylor

Grace Taylor
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
Do Medically Integrated Pharmacies Reduce the Abandonment Rate of Oral Anticancer Medications?
10/30/2023

Emry Lloyd

Emry Lloyd
Dr Doshi and colleagues measured the impact of medically integrated pharmacies on prescription medication abandonment rates.
Dr Doshi and colleagues measured the impact of medically integrated pharmacies on prescription medication abandonment rates.
Dr Doshi and colleagues measured...
10/30/2023
Journal of Clinical Pathways
News
The Impact of Lower Cost Alternatives or Biosimilars on The Cost of Key Cancer Drugs
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
The Impact of Dosing Approaches for Lenalidomide on Total Cost of Care
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
Access to Pediatric Palliative Care Assessed in Resource-Constrained Communities
10/27/2023

Emry Lloyd

Emry Lloyd
Dr Houston and colleagues assessed the care capacity and improvement strategies of pediatric institutions that care for children with cancer.
Dr Houston and colleagues assessed the care capacity and improvement strategies of pediatric institutions that care for children with cancer.
Dr Houston and colleagues...
10/27/2023
Journal of Clinical Pathways
News
Rollback of Prescription Delivery Flexibilities Poses Challenges for At-Risk Cancer Patients
10/27/2023

Brandon Twyford

Brandon Twyford
Research presented at the 2023 ASCO Quality Care Symposium revealed unequal impacts on patients from recent policy changes preventing home delivery of prescription oncology medication.
Research presented at the 2023 ASCO Quality Care Symposium revealed unequal impacts on patients from recent policy changes preventing home delivery of prescription oncology medication.
Research presented at the 2023...
10/27/2023
Journal of Clinical Pathways
News
The Influence of End-of-Life Care Costs on Episodic Value-Based Care Models
10/26/2023

Emry Lloyd

Emry Lloyd
In this study, Gunjan Sharma, MS, and colleagues examine the impact of end-of-life costs on patients and caregivers, and how it influences value-based care models for physicians.
In this study, Gunjan Sharma, MS, and colleagues examine the impact of end-of-life costs on patients and caregivers, and how it influences value-based care models for physicians.
In this study, Gunjan Sharma,...
10/26/2023
Journal of Clinical Pathways
News
Virtual Consult Pilot Successfully Implemented in Integrated Health System
10/26/2023

Brandon Twyford

Brandon Twyford
An innovative virtual consult pilot launched by Kaiser Permanente saw success in bridging the gap between oncologists and cancer subspecialists within the organization.
An innovative virtual consult pilot launched by Kaiser Permanente saw success in bridging the gap between oncologists and cancer subspecialists within the organization.
An innovative virtual consult...
10/26/2023
Journal of Clinical Pathways

News

News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
US Cancer Centers Still Struggling with Chemotherapy Shortages, NCCN’s Recent Survey Reveals
11/04/2023

Brandon Twyford

Brandon Twyford
Results from NCCN's recent survey of cancer centers reveals a persisting shortage of chemotherapy drugs within the US, with 72% of centers reporting a shortage of carboplatin and 59% facing challenges with obtaining cisplatin.
Results from NCCN's recent survey of cancer centers reveals a persisting shortage of chemotherapy drugs within the US, with 72% of centers reporting a shortage of carboplatin and 59% facing challenges with obtaining cisplatin.
Results from NCCN's recent...
11/04/2023
Journal of Clinical Pathways
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023

Grace Taylor

Grace Taylor
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
Do Medically Integrated Pharmacies Reduce the Abandonment Rate of Oral Anticancer Medications?
10/30/2023

Emry Lloyd

Emry Lloyd
Dr Doshi and colleagues measured the impact of medically integrated pharmacies on prescription medication abandonment rates.
Dr Doshi and colleagues measured the impact of medically integrated pharmacies on prescription medication abandonment rates.
Dr Doshi and colleagues measured...
10/30/2023
Journal of Clinical Pathways
News
The Impact of Lower Cost Alternatives or Biosimilars on The Cost of Key Cancer Drugs
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
The Impact of Dosing Approaches for Lenalidomide on Total Cost of Care
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
Access to Pediatric Palliative Care Assessed in Resource-Constrained Communities
10/27/2023

Emry Lloyd

Emry Lloyd
Dr Houston and colleagues assessed the care capacity and improvement strategies of pediatric institutions that care for children with cancer.
Dr Houston and colleagues assessed the care capacity and improvement strategies of pediatric institutions that care for children with cancer.
Dr Houston and colleagues...
10/27/2023
Journal of Clinical Pathways
News
Rollback of Prescription Delivery Flexibilities Poses Challenges for At-Risk Cancer Patients
10/27/2023

Brandon Twyford

Brandon Twyford
Research presented at the 2023 ASCO Quality Care Symposium revealed unequal impacts on patients from recent policy changes preventing home delivery of prescription oncology medication.
Research presented at the 2023 ASCO Quality Care Symposium revealed unequal impacts on patients from recent policy changes preventing home delivery of prescription oncology medication.
Research presented at the 2023...
10/27/2023
Journal of Clinical Pathways
News
The Influence of End-of-Life Care Costs on Episodic Value-Based Care Models
10/26/2023

Emry Lloyd

Emry Lloyd
In this study, Gunjan Sharma, MS, and colleagues examine the impact of end-of-life costs on patients and caregivers, and how it influences value-based care models for physicians.
In this study, Gunjan Sharma, MS, and colleagues examine the impact of end-of-life costs on patients and caregivers, and how it influences value-based care models for physicians.
In this study, Gunjan Sharma,...
10/26/2023
Journal of Clinical Pathways
News
Virtual Consult Pilot Successfully Implemented in Integrated Health System
10/26/2023

Brandon Twyford

Brandon Twyford
An innovative virtual consult pilot launched by Kaiser Permanente saw success in bridging the gap between oncologists and cancer subspecialists within the organization.
An innovative virtual consult pilot launched by Kaiser Permanente saw success in bridging the gap between oncologists and cancer subspecialists within the organization.
An innovative virtual consult...
10/26/2023
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Interviews

Lee Fleisher, MD
Interview
CMS National Quality Strategy Focuses on Quality, Safety, Affordability Standards in Oncology Care
11/10/2022
Lee Fleisher, MD, outlines the foundation and goals of the Centers for Medicare and Medicaid Services’ National Quality Strategy, highlighting key components such as quality, safety, and affordability, and emphasizing alignment between all of...
Lee Fleisher, MD, outlines the foundation and goals of the Centers for Medicare and Medicaid Services’ National Quality Strategy, highlighting key components such as quality, safety, and affordability, and emphasizing alignment between all of...
Lee Fleisher, MD, outlines the...
11/10/2022
Journal of Clinical Pathways
Overcoming Resource, Reimbursement Barriers to Comprehensive Cancer Care Delivery
Interview
Overcoming Resource, Reimbursement Barriers to Comprehensive Cancer Care Delivery
07/10/2020
At the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program(May 29-31, 2020), the Association of Community Cancer Centers (ACCC) presented the preliminary results of a member survey on...
At the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program(May 29-31, 2020), the Association of Community Cancer Centers (ACCC) presented the preliminary results of a member survey on...
At the...
07/10/2020
Journal of Clinical Pathways
Gunjan Sharma
Interview
Leveraging Data to Enhance Patient Care: Addressing Social Determinants of Health in Oncology Care
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
Paul Fu, MD
Interview
How Technology Can Improve Health Care Team Communication
06/17/2024
Paul Fu Jr, MD, MPH, City of Hope National Medical Center
Paul Fu Jr, MD, MPH, discusses the benefits of using technology to assist health team communication practices.
Paul Fu Jr, MD, MPH, discusses the benefits of using technology to assist health team communication practices.
Paul Fu Jr, MD, MPH, discusses...
06/17/2024
Journal of Clinical Pathways
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shields Hea...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
Shaalan Beg, MD
Interview
CLL Treatment Updates and the Integration of AI into CLL Clinical Trials
05/20/2024
Shaalan Beg, MD, MBA, FASCO
Shaalan Beg, MD, MBA, FASCO, describes some of the recent advancements in the treatment of chronic lymphocytic leukemia (CLL).
Shaalan Beg, MD, MBA, FASCO, describes some of the recent advancements in the treatment of chronic lymphocytic leukemia (CLL).
Shaalan Beg, MD, MBA, FASCO,...
05/20/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Interview
Chronic Lymphocytic Leukemia Pathways in Practice at Rocky Mountain Cancer Centers
03/27/2024
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and describes how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and describes how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the...
03/27/2024
Journal of Clinical Pathways
Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
Jing-Zhou Hou, MD, PhD
Videos
Clinical and Demographic Factors Impacting Treatment Selection for Patients With CLL in Community Oncology Settings
03/21/2024

Featuring Jing-Zhou Hou, MD, PhD

Featuring Jing-Zhou Hou, MD, PhD ...
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD,...
03/21/2024
Journal of Clinical Pathways
Michiel van der Heijden, MD 
Conference Coverage
Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting
01/26/2024

Featuring Michiel van der Heijden, MD 

Featuring Michiel van der Heijden, MD...
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology

Blog

Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023

Jacqlyn Riposo, MBA; Tom Valuck, MD, JD

Jacqlyn Riposo, MBA; Tom Valuck, MD, ...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
Sarena Ho, MSPH
Quality Outlook
Quality Measures for Medicare’s Enhancing Oncology Model (EOM): New and Improved or More of the Same?
01/26/2023

David Blaisdell; Sarena Ho, MSPH; Tom Valuck, MD, JD

David Blaisdell; Sarena Ho, MSPH; Tom...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center...
01/26/2023
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024

Winston Wong, PharmD

Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Kendall Logan, MPH.
Quality Outlook
A Tale of Two States: Examining the Best and Worst Performing States for HPV Vaccination
02/12/2024

Kendall Logan, MPH; Anne DiSalvo, MPH, MBA; Erik Muther; Blog Editor: Tom Valuck, MD, JD

Kendall Logan, MPH; Anne DiSalvo, MPH...
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a...
02/12/2024
Journal of Clinical Pathways
Theresa Schmidt headshot.
Quality Outlook
2024 Quality Outlook Revealed: Insights from 2023 Fall Conferences
02/02/2024

Theresa Schmidt, MA; Danny Bellet, MBA; Donna Dugan, PhD, MS; Erik Muther; David Sloan, PhD; Tom Valuck, MD, JD

Theresa Schmidt, MA; Danny Bellet, MB...
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the...
02/02/2024
Journal of Clinical Pathways
Anne Disalvo headshot
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Racial and Ethnic Disparities in HPV Vaccination
11/10/2023

Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther; Blog Editor: Tom Valuck, MD, JD

Anne DiSalvo, MPH, MBA; Kendall Logan...
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a...
11/10/2023
Journal of Clinical Pathways
Anne DiSalvo.
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Geographic Disparities in HPV Vaccination
10/03/2023

Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther; Blog Editor: Tom Valuck, MD, JD

Anne DiSalvo, MPH, MBA; Kendall Logan...
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part...
10/03/2023
Journal of Clinical Pathways
David Blaisdell, BA, Real Chemistry.
Quality Outlook
Enhancing Value-Based Oncology Care: What Has CMMI Learned From the OCM?
09/22/2023

David Blaisdell; Blog Editor: Tom Valuck, MD, JD

David Blaisdell; Blog Editor: Tom Val...
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about...
09/22/2023
Journal of Clinical Pathways
Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023

Jacqlyn Riposo, MBA; Tom Valuck, MD, JD

Jacqlyn Riposo, MBA; Tom Valuck, MD, ...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
Winston Wong
Editor Insights
A Look Back at Clinical Pathways in 2022
02/21/2023
Winston Wong, PharmD, Editor-in-Chief
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal...
02/21/2023
Journal of Clinical Pathways
Sarena Ho, MSPH
Quality Outlook
Quality Measures for Medicare’s Enhancing Oncology Model (EOM): New and Improved or More of the Same?
01/26/2023

David Blaisdell; Sarena Ho, MSPH; Tom Valuck, MD, JD

David Blaisdell; Sarena Ho, MSPH; Tom...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center...
01/26/2023
Journal of Clinical Pathways

Videos

Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Video preview image.
Videos
St. Elizabeth’s Innovative Cancer Screening Outreach Model
09/22/2023

Featuring Michael Gieske, MD, and Jamie Ries, RN, BSN

Featuring Michael Gieske, MD, and Jam...
Michael Gieske, MD, and Jamie Ries, RN, BSN, speak about the development of a care delivery model that demonstrates sustainable outreach for cancer screening, with a specific focus on at-risk and underserved patient populations.
Michael Gieske, MD, and Jamie Ries, RN, BSN, speak about the development of a care delivery model that demonstrates sustainable outreach for cancer screening, with a specific focus on at-risk and underserved patient populations.
Michael Gieske, MD, and Jamie...
09/22/2023
Journal of Clinical Pathways
Puneeth Indurlal, MD
Videos
Impact of Dose Rounding Bevacizumab and its Biosimilars on Total Cost of Care for OCM Participants
07/26/2023

Featuring Puneeth Indurlal, MD

Featuring Puneeth Indurlal, MD ...
Puneeth Indurlal, MD, discusses the impact of dose rounding that targets bevacizumab and its biosimilars on the total cost of care and drug waste expenditures for Oncology Care Model participants in the US Oncology Network.
Puneeth Indurlal, MD, discusses the impact of dose rounding that targets bevacizumab and its biosimilars on the total cost of care and drug waste expenditures for Oncology Care Model participants in the US Oncology Network.
Puneeth Indurlal, MD, discusses...
07/26/2023
Journal of Clinical Pathways
Monica Schmidt, PhD.
Videos
The Impact of Elsevier ClinicalPath Oncology Treatment Pathways on Survival and Cost of Care
07/24/2023

Featuring Monica Schmidt, PhD

Featuring Monica Schmidt, PhD
In an interview with the Journal of Clinical Pathways, Monica Schmidt, PhD, MPH, discusses her study on the impact of using Elsevier’s ClinicalPath oncology pathways on short-term survival and cost of care from the patient and health system...
In an interview with the Journal of Clinical Pathways, Monica Schmidt, PhD, MPH, discusses her study on the impact of using Elsevier’s ClinicalPath oncology pathways on short-term survival and cost of care from the patient and health system...
In an interview with the Journal...
07/24/2023
Journal of Clinical Pathways
Aaron P. Mitchell, MD, MPH
Videos
Study Examines the Association Between Oncologists’ Receipt of Pharmaceutical Industry Payments and Use of Nonrecommended/Low-Value Treatments
07/20/2023

Featuring Aaron P. Mitchell, MD

Featuring Aaron P. Mitchell, MD ...
Aaron P. Mitchell, MD, MPH, discusses his research on the association of pharmaceutical industry payments to oncologists and their increased use of nonrecommended and/or low-value treatment methods.
Aaron P. Mitchell, MD, MPH, discusses his research on the association of pharmaceutical industry payments to oncologists and their increased use of nonrecommended and/or low-value treatment methods.
Aaron P. Mitchell, MD, MPH,...
07/20/2023
Journal of Clinical Pathways
Patricia Santos, MD
Videos
Health Care Access and Affordability for Adult Immigrant Cancer Survivors
06/26/2023

Featuring Patricia Santos, MD

Featuring Patricia Santos, MD
Patricia Santos, MD, Memorial Sloan Kettering Cancer Center, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about her research on the coverage and affordability of health care access for adult immigrant cancer...
Patricia Santos, MD, Memorial Sloan Kettering Cancer Center, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about her research on the coverage and affordability of health care access for adult immigrant cancer...
Patricia Santos, MD, Memorial...
06/26/2023
Journal of Clinical Pathways
Lalan Wilfong, MD.
Conference Coverage
Benefits and Challenges of the Enhancing Oncology Model
06/13/2023
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting,...
06/13/2023
Journal of Clinical Pathways
Dr Daniel Virnich, President, the Oncology Institute.
Videos
A Value-based Framework for Drug Cost Support and Funding Programs
05/11/2023
Dr Daniel Virnich, President, The Oncology Institute, discusses his presentation on drug cost support and funding programs for patients with cancer from Oncology at Total Health 2022.
Dr Daniel Virnich, President, The Oncology Institute, discusses his presentation on drug cost support and funding programs for patients with cancer from Oncology at Total Health 2022.
Dr Daniel Virnich, President,...
05/11/2023
Journal of Clinical Pathways
Adria Warren, Partner at Foley & Lardner LLP
Videos
New Developments in the 340B Drug Pricing Program
04/03/2023
Adria Warren, health care transactional partner at Foley & Lardner LLP, spoke with the Journal of Clinical Pathways about new developments in the 340B drug pricing program and provided updates on recent court rulings and cases in process that...
Adria Warren, health care transactional partner at Foley & Lardner LLP, spoke with the Journal of Clinical Pathways about new developments in the 340B drug pricing program and provided updates on recent court rulings and cases in process that...
Adria Warren, health care...
04/03/2023
Journal of Clinical Pathways
Lee Fleisher, MD
Videos
Making Clinical Pathways Unique to the Patient Journey
11/14/2022
Lee Fleisher, MD, discusses balancing the need for uniform quality care for all patients with finding the proper pathways for individual patients.
Lee Fleisher, MD, discusses balancing the need for uniform quality care for all patients with finding the proper pathways for individual patients.
Lee Fleisher, MD, discusses...
11/14/2022
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
Chronic Lymphocytic Leukemia Treatment Updates
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Why People Should Care About How Health Care Works (Part 1)
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
Characteristics of Clinical Trials in Community Oncology Practices Across the US
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Show Me the Medical Evidence
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
BDHC thumbnail
Breaking Down Health Care
What Does Quality Mean in Health Care?
07/01/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, examine how to measure quality in health care and the current challenges with the existing methods.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, examine how to measure quality in health care and the current challenges with the existing methods.
In this Breaking Down Health...
07/01/2024
Cancer Care Business Exchange
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Tony Mok, MD
Conference Coverage
Adagrasib Improved Survival and Response Among Patients With KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
06/17/2024
Tony Mok, MD
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the...
06/17/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
US Cancer Centers Still Struggling with Chemotherapy Shortages, NCCN’s Recent Survey Reveals
11/04/2023

Brandon Twyford

Brandon Twyford
Results from NCCN's recent survey of cancer centers reveals a persisting shortage of chemotherapy drugs within the US, with 72% of centers reporting a shortage of carboplatin and 59% facing challenges with obtaining cisplatin.
Results from NCCN's recent survey of cancer centers reveals a persisting shortage of chemotherapy drugs within the US, with 72% of centers reporting a shortage of carboplatin and 59% facing challenges with obtaining cisplatin.
Results from NCCN's recent...
11/04/2023
Journal of Clinical Pathways
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023

Grace Taylor

Grace Taylor
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
Do Medically Integrated Pharmacies Reduce the Abandonment Rate of Oral Anticancer Medications?
10/30/2023

Emry Lloyd

Emry Lloyd
Dr Doshi and colleagues measured the impact of medically integrated pharmacies on prescription medication abandonment rates.
Dr Doshi and colleagues measured the impact of medically integrated pharmacies on prescription medication abandonment rates.
Dr Doshi and colleagues measured...
10/30/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement